Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Informed Consent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,961 result(s) found for: Informed Consent. Displaying page 713 of 1,449.
    «« First « Previous 709  710  711  712  713  714  715  716  717  Next» Last»»
    EudraCT Number: 2006-004667-61 Sponsor Protocol Number: SUITE - CUOG-TE 05 Start Date*: 2007-02-22
    Sponsor Name:Universitätsklinikum Hamburg-Eppendorf
    Full Title: Prospective open-labeled non randomized Phase-II study of SU011248 (Sunitinib) in male patients with relapsed or cisplatin-refractory germ cell cancer - A CUOG/GTCSG cooperative phase II study
    Medical condition: germ cell cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061378 Testicular germ cell cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006515-76 Sponsor Protocol Number: REO 011 Start Date*: 2007-01-08
    Sponsor Name:Oncolytics Biotech Inc
    Full Title: A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Car...
    Medical condition: Advanced or metastatic solid tumours that are refractory to standard therapy or for which no curative standard therapy exists and for which paclitaxel plus carboplatin is appropriate palliative che...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-018054-33 Sponsor Protocol Number: 09-001 Start Date*: 2010-06-21
    Sponsor Name:Faculty of Pharmacy, University of Ljubljana
    Full Title: Efficacy of vitamin E and omega-3 unsaturated fatty acid in prevention of damage induced by oxidative stress in patients with schizophrenia
    Medical condition: Patients diagnosed with schizophrenia chronically treated with depo haloperidol will be randomly assigned to four arms; i) placebo, ii) vitamin E (1200 IU/day), iii) omega-3 (360 mg/day EPA, 240 mg...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: View results
    EudraCT Number: 2021-002821-32 Sponsor Protocol Number: FENDEEP Start Date*: 2021-12-09
    Sponsor Name:Neurologia Aplicada, SLP
    Full Title: The FENDEEP Study: Fenfluramine for the treatment of different types of developmental and epileptic encephalopathies: a pilot trial exploring epileptic and non-epileptic outcomes.
    Medical condition: Five different types of developmental and epileptic encephalopathies (DEEs): SYNGAP1 and STXBP1 encephalopathies, inv-dup(15) encephalopathy, multifocal or bilateral Malformations of Cortical Devel...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10053551 Intractable epilepsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000353-31 Sponsor Protocol Number: DEEP-2 Start Date*: 2012-11-29
    Sponsor Name:CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE
    Full Title: Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to l...
    Medical condition: Chronic iron overload
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10065974 Chronic iron overload LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) Outside EU/EEA GR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002053-30 Sponsor Protocol Number: EMR200095-005 Start Date*: 2014-05-16
    Sponsor Name:Merck KGaA
    Full Title: A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liv...
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002551-22 Sponsor Protocol Number: HZA114971 Start Date*: 2017-02-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg once dai...
    Medical condition: Paediatric Subjects with Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019859-21 Sponsor Protocol Number: PMR-EC-1501 Start Date*: 2011-05-05
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: A Phase II, Open Label, Parallel Group, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Adult Subjects Undergoing Primary Allograft Transplantation Receiving an Advagraf® or Pro...
    Medical condition: Prophylaxis of primary heart, lung, pancreas, (including simultaneous pancreas kidney [SPK]) organ transplant rejection.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050433 Prophylaxis against lung transplant rejection LLT
    12.1 10050432 Prophylaxis against heart transplant rejection LLT
    12.1 10050435 Prophylaxis against pancreas transplant rejection LLT
    12.1 10050438 Prophylaxis against renal and pancreas transplant rejection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002005-36 Sponsor Protocol Number: RM-493-015 Start Date*: 2017-10-30
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Leptin Receptor (LEPR) Deficiency...
    Medical condition: Early Onset Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005192-89 Sponsor Protocol Number: C1231001 Start Date*: 2015-04-21
    Sponsor Name:Hospira UK Ltd.
    Full Title: Post-Marketing Observational Cohort Study of Patients with Inflammatory Bowel Disease (IBD) Treated with CT-P13 in Usual Clinical Practice (CONNECT-IBD)
    Medical condition: Inflamatory Bowel Disease (IBD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10021973 Inflammatory bowel disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-005048-97 Sponsor Protocol Number: SP905 Start Date*: 2007-05-03
    Sponsor Name:SCHWARZ BIOSCIENCES GmbH
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF 400MG/DAY LACOSAMIDE IN SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE
    Medical condition: Osteoarthritis of the knee
    Disease: Version SOC Term Classification Code Term Level
    8.1 10031165 Osteoarthritis knee LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) CZ (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005425-30 Sponsor Protocol Number: AURA-6202-011 Start Date*: 2008-04-17
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: An Exploratory Phase II Study of PHA-739358 in Patients with Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression
    Medical condition: Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005326-29 Sponsor Protocol Number: IBCSG_41-13 Start Date*: 2013-11-11
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for locally advanced endocrine r...
    Medical condition: Premenopausal patients with histologically confirmed locally advanced breast cancer and with primary tumor of ER+/PgR+ and HER2 negative or not amplified.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007588-26 Sponsor Protocol Number: A7941006 Start Date*: 2008-04-04
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12-WEEK ADMINISTRATION OF PF-00734200 TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS ...
    Medical condition: PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON METFORMIN TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003307-30 Sponsor Protocol Number: RA0123 Start Date*: 2015-04-16
    Sponsor Name:UCB Celltech, UK Registered Branch of UCB Pharma SA
    Full Title: A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Doses of UCB4940 Administered as Add-On to Certolizumab Pegol...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004891-36 Sponsor Protocol Number: L00074TD301 Start Date*: 2005-04-01
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: CROSS-OVER COMPARISON OF TESTOSTERONE SERUM LEVELS IN HYPOGONADAL MEN TREATED WITH L0074 TESTOSTERONE PATCH 60CM2 (2 patches/48H) AND ORAL TESTOSTERONE UNDECANOATE -PANTESTONE® 40mg- (2 caps, bid)
    Medical condition: Men aged > 18 years old with primary or secondary hypogonadism. Only patients meeting the inclusion criteria will be enrolled in this study.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10021011 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002384-16 Sponsor Protocol Number: TTD-11-01/AXI-IIG-01 Start Date*: 2011-09-21
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: A Phase II study of Axitinib as maintenance for patients with advanced colorectal carcinoma.
    Medical condition: Advanced colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000734-19 Sponsor Protocol Number: XCEL-MS-02 Start Date*: 2014-04-10
    Sponsor Name:Banc de Sang i Teixits
    Full Title: Treatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-018585-23 Sponsor Protocol Number: A4061051 Start Date*: 2010-12-21
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017
    Full Title: AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC)
    Medical condition: metastatic renal cell cancer
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-004833-25 Sponsor Protocol Number: UNLOCK Start Date*: 2017-03-29
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar)
    Full Title: Synchronous effect of anesthetics on fMRI, EEG and clinical responses. Development of a more precise system for monitoring anesthetic effect.
    Medical condition: General anaesthesia in healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 709  710  711  712  713  714  715  716  717  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 22:26:01 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA